{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:06:23Z","timestamp":1784934383905,"version":"3.55.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/fpc.0b013e32830e1e16","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T07:34:46Z","timestamp":1223969686000},"page":"943-953","source":"Crossref","is-referenced-by-count":48,"title":["Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease"],"prefix":"10.1097","volume":"18","author":[{"given":"Helen E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Kalhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico M.","family":"Farin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Stapleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Blough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Thummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rheem A.","family":"Totah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210212","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1358\/dnp.2003.16.5.829315","article-title":"Molecular actions of calcineurin inhibitors","volume":"16","author":"Hamawy","year":"2003","journal-title":"Drug News Perspect"},{"key":"R2-3-20210212","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1600-6143.2005.00808.x","article-title":"A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status","volume":"5","author":"Lucey","year":"2005","journal-title":"Am J Transplant"},{"key":"R3-3-20210212","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1046\/j.1523-1755.1998.00202.x","article-title":"Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line","volume":"54","author":"Healy","year":"1998","journal-title":"Kidney Int"},{"key":"R4-3-20210212","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0168-8278(00)80426-2","article-title":"Liver transplantation","volume":"32","author":"Neuberger","year":"2000","journal-title":"J Hepatol"},{"key":"R5-3-20210212","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/00007890-200105150-00017","article-title":"Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation","volume":"71","author":"Vincenti","year":"2001","journal-title":"Transplantation"},{"key":"R6-3-20210212","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-3-20210212","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1523-1755.2005.00558.x","article-title":"Posttransplantation chronic renal damage in nonrenal transplant recipients","volume":"68","author":"Stratta","year":"2005","journal-title":"Kidney Int"},{"key":"R8-3-20210212","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"key":"R9-3-20210212","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.tp.0000185305.63759.d3","article-title":"ACE gene D\/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients","volume":"81","author":"Gallon","year":"2006","journal-title":"Transplantation"},{"key":"R10-3-20210212","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1681\/ASN.2004100882","article-title":"ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation","volume":"16","author":"Hauser","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R11-3-20210212","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00008571-200311000-00002","article-title":"Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors","volume":"13","author":"Hebert","year":"2003","journal-title":"Pharmacogenetics"},{"key":"R12-3-20210212","doi-asserted-by":"crossref","first-page":"F965","DOI":"10.1152\/ajprenal.2000.279.6.F965","article-title":"Eicosanoid regulation of the renal vasculature","volume":"279","author":"Imig","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"R13-3-20210212","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI3985","article-title":"The relationship of hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis","volume":"103","author":"Mallat","year":"1999","journal-title":"J Clin Invest"},{"key":"R14-3-20210212","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1126\/science.285.5431.1276","article-title":"Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids","volume":"285","author":"Node","year":"1999","journal-title":"Science"},{"key":"R15-3-20210212","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0003-9861(95)90023-3","article-title":"Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes","volume":"320","author":"Rifkind","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"R16-3-20210212","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol Rev"},{"key":"R17-3-20210212","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1152\/ajpregu.00713.2003","article-title":"Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis","volume":"287","author":"Dos Santos","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R18-3-20210212","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.HYP.0000090123.55365.BA","article-title":"Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension","volume":"42","author":"Wang","year":"2003","journal-title":"Hypertension"},{"key":"R19-3-20210212","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0026-895X(24)26512-3","article-title":"Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney","volume":"57","author":"Yu","year":"2000","journal-title":"Mol Pharmacol"},{"key":"R20-3-20210212","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.0000143832.91812.60","article-title":"Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2","volume":"110","author":"Spiecker","year":"2004","journal-title":"Circulation"},{"key":"R21-3-20210212","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1006\/abbi.1996.0229","article-title":"Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway","volume":"330","author":"Zeldin","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"R22-3-20210212","first-page":"266","article-title":"Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism","volume":"4","author":"Rodriguez-Antona","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"R23-3-20210212","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/lt.20017","article-title":"Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations","volume":"10","author":"Gonwa","year":"2004","journal-title":"Liver Transpl"},{"key":"R24-3-20210212","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1021\/bi002305w","article-title":"Interaction of apo-cytochrome b5 with cytochromes P4503A4 and P45017A: relevance of heme transfer reactions","volume":"40","author":"Guryev","year":"2001","journal-title":"Biochemistry"},{"key":"R25-3-20210212","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1073\/pnas.88.13.5597","article-title":"Expression and enzymatic activity of recombinant cytochrome P450 17 alpha-hydroxylase in Escherichia coli","volume":"88","author":"Barnes","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-3-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0003-9861(03)00278-9","article-title":"Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group","volume":"416","author":"Cheesman","year":"2003","journal-title":"Arch Biochem Biophys"},{"key":"R27-3-20210212","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000099150","article-title":"Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney","volume":"30","author":"McGuire","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"R28-3-20210212","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13685530701419096","article-title":"Chronic kidney disease (CKD) in the elderly \u2013 a geriatrician's perspective","volume":"10","author":"Munikrishnappa","year":"2007","journal-title":"Aging Male"},{"key":"R29-3-20210212","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/002215540405200403","article-title":"Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues","volume":"52","author":"Enayetallah","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"R30-3-20210212","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R31-3-20210212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0009-9236(99)70104-9","article-title":"Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients","volume":"65","author":"Muck","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R32-3-20210212","first-page":"3379","article-title":"Coadministration of oral cyclosporin A enables oral therapy with paclitaxel","volume":"5","author":"Meerum Terwogt","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R33-3-20210212","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","article-title":"Cyclosporine markedly raises the plasma concentrations of repaglinide","volume":"78","author":"Kajosaari","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R34-3-20210212","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clpt.2004.12.267","article-title":"Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance","volume":"77","author":"Totah","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"R35-3-20210212","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2125.2003.01870.x","article-title":"Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients","volume":"56","author":"Renders","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R36-3-20210212","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.87.11.992","article-title":"Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids","volume":"87","author":"Yu","year":"2000","journal-title":"Circ Res"},{"key":"R37-3-20210212","first-page":"1244","article-title":"Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage","volume":"15","author":"Zhao","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R38-3-20210212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0006-291X(02)02592-5","article-title":"Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms","volume":"299","author":"Yasar","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"R39-3-20210212","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1111\/j.1600-6143.2006.01456.x","article-title":"Cyclosporine A increases plasma concentrations and effects of repaglinide","volume":"6","author":"Backman","year":"2006","journal-title":"Am J Transplant"},{"key":"R40-3-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/14622416.8.2.187","article-title":"CYP2C8 and antimalaria drug efficacy","volume":"8","author":"Gil","year":"2007","journal-title":"Pharmacogenomics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-200811000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T19:00:50Z","timestamp":1738436450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200811000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32830e1e16","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}